DaVita Clinical Research Expands Capabilities With Investments in Central Laboratory
DaVita Clinical Research
announced the company’s recent investment in its Central Laboratory, servicing pharmaceutical, biotechnology, and medical device industries.
The investment was applied to analytical methodology, information technology (IT), and instrumentation in support of DCR’s continued drive to serve its clients. Over the past three years, DCR has had a strategic focus on Central Laboratory services, investing in state-of-the-art capital equipment, infrastructure and laboratory expansion/remodeling. The investment was placed in DCR’s Central Laboratory to ensure continuous delivery of customized care and satisfaction to its patients.
The Central Laboratory uses the latest in laboratory instrumentation. Some examples of the lab’s instrumentation and test menu include:
- 7 Olympus 5400
- 17 Siemens Centaur
- 9 Tosoh G-8
- 2 Liaison Diasorin
- 8 Perkin-Elmer ICP-MS
- 2 Nova
- 2 Dianex
- 23 Siemens Advia 2120
- 2 TOPS Coagulation
- 19 BACTEC 9240
- 14 Lonza BioTek
- 4 Vitek-2
DCR’s Central Laboratory also has invested in such technology as centrifuges, auto samplers, slide strainers, incubators, biosafety cabinets and decappers. DCR’s investment assisted in expanding and remodeling the laboratory, adding space to help facilitate future service expansion. In addition, extensive investment in its Falcon LabTM software application has resulted in the latest release, which includes an industry-leading report package.
At DCR’s Central Laboratory, individual trial samples are tracked using
LabScope Online
®, which ensures most specimen turnaround time of 24 hours or less.
The DCR Central Laboratory team is led by medical technologists, medical technicians and clinical pathologists, and receives formal guidance from nephrologists in the industry.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
